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Background: Medication non-adherence is a major challenge in the real-life treatment of chronically ill patients. To
meet this challenge, adherence interventions with a tailored approach towards patient-specific adherence barriers
that are identified with a reliable and practicable questionnaire are needed. The aim of this investigation was to
develop and validate such a questionnaire, the “Adherence Barriers Questionnaire (ABQ)”.
Methods: The German ABQ was developed and tested in 432 patients with atrial fibrillation in a multicentre
observational cohort study. Evaluation of the questionnaire included an assessment of internal consistency as well
as factor analysis. Criterion-related external validity was assessed by comparing the ABQ score with (1) the degree
of self-reported adherence and (2) the time in therapeutic range which describes the anticoagulation quality
achieved by patients treated with oral anticoagulation.
Results: The final 14-item ABQ scale demonstrated high internal consistency (Cronbach’s alpha = 0.820). Factor
analysis identified a three-factor solution, representing intentional adherence barriers with 5 items (31.9% of the
variance), medication-/health care system-related adherence barriers with 5 items (13.3% of the variance) and
unintentional adherence barriers with 4 items (7.7% of the variance).
The ABQ correlated significantly with self-reported non-adherence (Spearman’s rho = 0.438, p < 0.001) as well as
time in therapeutic range (Spearman’s rho = − 0.161, p < 0.010). Patients with above-average ABQ scores
(increased number and/or strength of existing adherence barriers) were significantly (p < 0.005, Pearson
Chi-Square) more likely to have a poor anticoagulation quality (TTR < 60%) than patients with a lower ABQ score
(44.6% versus 27.3%).
Conclusions: The ABQ is a practicable, reliable and valid instrument for identifying patient-specific barriers to
medication-related adherence. Future research is required to examine the ability of the ABQ to identify patient
perception/behaviour changes over time which may be important for the measurement of success of adherence
interventions.
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Appropriate medication adherence, which can be de-
fined as the extent to which a patient’s drug-taking be-
haviour corresponds with agreed instructions from a
health care provider [1-3], is essential for realising the
potential health benefits of a certain medication-based
treatment [1-5]. Many patients, especially those with
chronic diseases, experience difficulties in adhering to a
recommended treatment plan, and medication non-
adherence (NA) with average rates of affected patients of
about 30-50% is a major challenge in the real-life treat-
ment of those patients [3-5].
To meet this challenge and improve patient outcomes,
it is important to develop both effective and practical in-
terventions for enhancing medication adherence. In the
last years, a high number of scientific publications con-
firmed the need for improving medication-related adher-
ence [2,6-8]. But there is an obvious lack of efficacy of
existing adherence interventions/programs [2,9,10], es-
pecially with regards to improvements of long-term ad-
herence and of associated clinical outcomes [11].
Available evidence shows that there are multiple reasons
for this lack of efficacy. One of these reasons may be the
inability of most of the interventions/programs to cus-
tomise adherence interventions on patient-specific needs
and preferences [3]. Moreover, existing research regard-
ing factors causing medication-related NA, which we
will call adherence barriers, shows that there is a variety
of explanations for that phenomenon, and that these dif-
ferent factors explain medication-related NA in specific
patients to a completely different extent. So, recent re-
search proposes to differentiate, at a minimum, between
intentional and unintentional NA [3,12-14]. Similarly to
this, the World Health Organization (WHO) described
NA as being a complex and multidimensional construct,
which is related to socio-economic factors, health care
system-related, and disease- and therapy-specific as well
as patient-related factors [5]. So, to ensure efficacy of ad-
herence interventions a tailored approach towards patient-
specific adherence barriers is needed. Consequently, lack
of knowledge with regards to the importance of specific
adherence barriers in a specific patient leads to a lack of
efficacy of adherence interventions.
If adherence interventions/programs need to consist of
patient-specific barrier-reducing measures [5-9], a reli-
able and practical tool for identification of those barriers
is needed.
In the past, some adherence self-report instruments,
which assessed both the degree of non-adherence as well
as reasons of observed non-adherence, have been devel-
oped. One example is the Morisky Medication Adher-
ence Scale (MMAS) [15], which has shown suitability in
verification of NA but generates limited information
about the predictors influencing NA. Moreover, it hardlycovers all of the known adherence barriers. Conse-
quently, it has been validated as instrument assessing
the degree of non-adherence only. Other instruments,
like the Brief Medication Questionnaire or the Beliefs
about Medicines Questionnaire [16,17], only addresses
specific domains of barriers (e.g. patient beliefs). Fur-
thermore, there are questionnaires addressing different
categories of barriers in a more detailed manner, but
these questionnaires are generally disease-specific instru-
ments [18,19] and, therefore, of limited suitability for
use in general clinical practice. Correspondingly, a review
analysing 43 different adherence scales showed that, so far,
there has been less focus on exploring patient-specific bar-
riers and how information may be useful in supporting
wise medicine use [20].
The aim of this study was, therefore, to develop a
questionnaire, called “Adherence Barriers Questionnaire
(ABQ)”, which measures (1) whether any adherence bar-
riers are present in a patient, and (2) to which of the
most important categories these barriers belong.
Methods
Item development and ABQ questionnaire
By conducting a systematic review of the relevant litera-
ture in the years 2008–2010 (see Additional file 1), the
most frequent observable factors associated with medi-
cation related NA were identified; an updated review
after data analysis that had been done revealed that no
additional general adherence barriers were discussed in
recent years (see Additional file 2). Generally, in accord-
ance with existing literature, the identified adherence
barriers could be classified into four main groups:
– Medication-related barriers: Most frequently observed
adherence barriers were the complexity of medication
regimes [21-23] and fear of/experience with side-effects
[24,25].
– Health care system-related barriers: In this category,
the direct/indirect medication-related costs patients
have to bear (co-payments, waiting times, long journeys
to reach the doctor, etc.) as well as a poor patient-
physician relationship were the most frequently
observed barriers [26-29].
– Patient-related unintentional barriers: Factors associated
with unintentional NA are those such as depression
[30,31], dementia, or the level of forgetfulness or the
degree of carefulness [31-34].
– Patient-related intentional barriers: Existing research
shows that intentional barriers may be the most
important single adherence barrier [3,12,33]; general
attitudes towards the treatment, the health-care
system and medication or health beliefs [17,35], as well
as coping behaviour [36-38] are the most important
influencing elements of intentional adherence.
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team consisting of all authors and formed the basis for
item construction. A total of 16 items addressing all de-
scribed adherence barriers were considered for the initial
version of the ABQ. Each item was formulated as a
statement. With regards to the response structure, a rat-
ing scale was chosen by assessing the grade of informa-
tion exploitation and, on the other hand, the risk of
overtaxing respondents. Finally, a 4-point Likert scale
was defined, which deliberately left out a mean response
option to force the respondents to a decision. The pos-
sible answers were “strongly agree”, “generally agree”,
“generally disagree”, and “strongly disagree”, which were
given values from 1 to 4 or rather 4 to 1 depending on
the formulation of each item (a higher score indicated a
higher influence of a certain barrier on patient’s percep-
tions). Based on patients’ responses, a general as well as
item- and subscale-specific ABQ scores indicating the
number and strength of adherence barriers present in a
patient were calculated.
In general, patients’ self-reports always face the risk that
the information provided by respondents may be dis-
torted, even with a pre-defined response scale. In particu-
lar, social desirability bias could be a problem in terms of
adherence-related questions. To control for the tendency
of respondents to answer in a manner that will be viewed
favourably by health care providers (or others), we added
five more questions at the end of the interview. For this
purpose, three items of the Social Desirability Scale-17
[39] were adopted and supplemented by two other health-
related items. The items were also formulated as state-
ments and could be answered either with “yes” or “no”.
All items were aligned so that the answer “yes” indicated a
stronger socially desirable response bias. These additional
items were not part of the ABQ, but were used for assess-
ment of the validity of the ABQ in subgroups classified by
high/low social desirability response bias.
Survey
We applied the ABQ in a multicentre, non-interventional,
prospective observational cohort study addressing the
general treatment of patients with atrial fibrillation (AF) in
general practices in Germany (ACT-AF study). Written in-
formed consent was obtained from each patient in this
study and the study protocol was approved by an inde-
pendent ethical committee. AF is the most common sig-
nificant cardiac rhythm disorder that is associated with
substantial lethality from stroke and thromboembolism.
According to current guidelines, a treatment with oral
anticoagulation is recommended for AF patients with a
high risk of stroke [40]. Non-adherence to oral anticoagu-
lation (OAC) seems to be a considerable problem and
leads to an increase in adverse medical events, including
stroke and bleeding events [41].In the ACT-AF study, 71 participating general practi-
tioners (GPs) were asked to include AF patients (ICD10
code I48; no further criteria) who were at least 18 years
old and not participating in any other study (first patient
in: May 2009, last patient out: May 2011). The data
documented in the study included the clinical and
sociodemographic background of each patient as well as
anticoagulation treatment information and all inter-
national normalised ratio (INR) values related to
anticoagulation therapy of the patients in the prospective
observational period of 12 months; new oral anticoagu-
lants were not available at the time of the study so that
anticoagulation was based on vitamin-K-antagonists
(VKA) only. Additional data were collected via written
questionnaires at the end of the study period; this last
survey took place on average 290.6 days after study in-
clusion. In our analysis, we included only patients who
participated in this last survey; for the statistical ana-
lyses, only data regarding patients who completed the
ABQ without any data gaps were used.
The developed ABQ was applied in its written form in
a patient survey at study sites. Furthermore, during this
survey, patients were asked to fill out a self-report in-
strument that measured the extent of potential NA
(modified “Adherence to Refills and Medications Scale –
ARMS” [42]). The ARMS is a validated instrument (one
of the few questionnaires which were validated using at
least two different external criteria and, among them, at
least one was a clinical outcome). Furthermore, the
ARMS contains hardly any questions which measure ad-
herence barriers; in this respect, it focuses on assessing
the level of non-adherence. Nevertheless, the original
ARMS had to be reduced by two items that rather
seemed to measure causes of NA (carelessness and cost)
than the extent of NA. The modified ARMS consisted of
10 items (4-point Likert scales) with a total score from
10 to 40, wherein a higher score indicated higher non-
adherence (see Additional file 3).
The ACT-AF study protocol, which included all men-
tioned questionnaires, was approved by the Ethics
Commission of the University of Greifswald (Germany).
The ABQ as well as all other questionnaires were ap-
plied in the German language.
Questionnaire validation and statistical analysis
All analyses were conducted using SPSS Statistics 17.0
(2008 SPSS Inc.).
The internal consistency reliability of the ABQ was ex-
amined by calculating the Cronbach’s alpha, which de-
scribes the questionnaire’s homogeneity [43]. In general,
an alpha ≥ 0.8 is desirable [43,44]. Simultaneously, the
item-total correlation coefficient for the different items
was evaluated, where a correlation ≥ 0.3 is seen as ad-
equate [45].
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principal components exploratory factor analysis. This
analysis generates possible subscales that are represented
by sets of items within the questionnaire. The Kaiser-
Meyer-Olkin measure of sampling adequacy and Bartlett’s
test of sphericity were used to confirm the eligibility of the
database for using this factor analysis. The initial number
of factors was determined by using eigenvalues > 1 as well
as scree plots examination. Sets of items generated by the
Promax-rotated component matrix were assessed to de-
fine whether they fitted into the identified subdomains of
the questionnaire. Items with a loading of > 0.4 were con-
sidered to adequately represent a factor.
The external validity of the questionnaire was investi-
gated by using two different criteria. First, an assessment
of the Spearman’s rho correlation of the ABQ score with
the score of the used self-report adherence measure
(modified ARMS) was done by determining the amount
of correlation as a measure of the validity. In this ana-
lysis, only patients having completed the ABQ as well as
the modified ARMS scale were included.
Second, a Spearman’s rho correlation of the ABQ scale
with the available clinical outcome “time in therapeutic
range” (TTR) was conducted. The TTR is a patient-
specific assessment of the quality of oral anticoagulation
therapy, and indicates the proportion of treatment time
in which a patient’s INR value was in the pre-defined
therapeutic range (INR between 2.0 and 3.0). The TTR is
strongly correlated with the medication intake, and there-
fore, a good clinical indicator of medication-related adher-
ence. In this analysis, only patients having completed the
ABQ without any data gaps, having been prescribed VKA,
and with two INR values available during the prospective
observational period of the study, were included.
Furthermore, the proportion of patients with good
anticoagulation quality among respondents with high
versus low ABQ scores (above or below the median) was
compared by using a chi-square test. According to
current guidelines, a good anticoagulation quality can be
defined as TTR ≥ 60% (at least 60% of the observed days
are within the target range) [40]. The chi-square test
should confirm the hypothesis that patients with a high
number and/or above-average strength of existing adher-
ence barriers are less likely to reach this level of TTR.
To consider a potential social desirability bias, all de-
scribed analyses for assessing the criterion-related valid-
ity were repeated separately in patients without a high
tendency to answer in a manner that will be viewed
favourably by health care providers. This tendency was
appraised by an additional scale gained from the last five
questions addressing social desirability with a score ran-
ging from 0 to 5. Patients with a score of five were defined
as most probably biased regarding social desirability, and
were excluded.Results
Adherence Barriers Questionnaire (ABQ)
Our developed ABQ consisted of 16 different items.
Five items referred to intentional adherence barriers
(items 4, 5, 6, 7, 12), four items to unintentional adherence
barriers (items 2, 9, 10, 13), four items to medication-
related barriers (items 11, 14, 15a, 15b), and three items to
health care system-related barriers (items 1, 3, 8).
Sample characteristics
Of the 786 AF-patients registered in the ACT-AF study,
570 (72.5%) participated in the survey. However, 138 pa-
tients did not respond to all ABQ questions, so that 432
patients completed the ABQ questionnaire without any
data gaps. These 432 patients who formed the basis of
our analysis had a mean age of 72.7 years; 45.6% were fe-
male. These patients suffered from AF for 6.6 years on
average, and took a mean number of 6.6 long-term med-
ications as reported by the treating physician. Most fre-
quent observed comorbidities were hypertension (83.8%)
and diabetes (38.4%).
In the external validation analyses, two subsamples of
the sample of 432 patients were analysed. In the first
analysis (ABQ versus modified ARMS scale), 401 pa-
tients with completed responses to both the ABQ and
the modified ARMS questionnaire were included. Of
these patients 44.6% showed poor self-reported adher-
ence (ARMS scores below the median of 11). In the sec-
ond analysis, 371 patients with completed responses to
the ABQ, having received vitamin K antagonists as antic-
oagulation treatment, and having at least two INR value
measures available, were included. Table 1 shows the
main characteristics of the different patient samples.
ABQ distribution analysis
Each ABQ item was scored 1 to 4 with a higher score in-
dicating a stronger influence/importance of the specific
adherence barrier from a respondent’s point of view.
Table 2 displays the distribution characteristics of the
patients’ responses to the 16 ABQ items. Most of the
items showed a right-skewed distribution of the scores
and thus had similar effects on the answering pattern of
the patients (particularly important with regards to the
inter-item-correlation). The only exception was item 8
(“I feel that co-payments for medicines are a great bur-
den”), with a skewness of −0.135. This indicates that it
was difficult for patients to contradict this statement;
which is also illustrated by the mean and median of the
scores (item 8 showed the highest values with a mean of
2.66 and a median of 3.0).
Reliability
Cronbach’s α for the original ABQ-scale was 0.814 and
demonstrated a good internal consistency. Item-total
Table 1 Characteristics of the patient samples











ABQ and the modified
ARMS scale
AF patients with complete
ABQ data, who received VKA
treatment and with at least
2 INR values available
N 786 570 432 401 371
Average age in years 73.17 (SD: 9.24) 73.08 (SD: 9.12) 72.74 (SD: 9.34) 73.09 (SD: 8.73) 72.79 (SD: 8.92)
Female gender 360 (45.8%) 264 (46.3%) 197 (45.6%) 178 (44.4%) 162 (43.7%)
Ø CHA2DS2-VASc score
+ 3.76 (SD: 1.63) 3.86 (SD: 1.62) 3.84 (SD: 1.66) 3.89 (SD: 1.63) 3.82 (SD: 1.64)
Ø Duration since first AF diagnosis in years 6.25 (SD: 5.43) 6.59 (SD: 5.83) 6.59 (SD: 5.83) 6.80 (SD: 5.73) 6.60 (SD: 5.34)
Average number of prescribed long-term
medications as reported by treating physicians
6.33 (SD: 2.65) 6.32 (SD: 2.62) 6.62 (SD: 5.55) 6.30 (SD: 2.58) 6.25 (SD: 2.55)
Living arrangements
Living alone 240 (30.5%) 167 (29.3%) 125 (28.9%) 114 (28.4%) 105 (28.3%)
Living with a partner 530 (67.4%) 392 (68.8%) 299 (69.2%) 279 (69.6%) 260 (70.1%)
Living in a care home 16 (2.1%) 11 (1.9%) 8 (1.9%) 8 (2.0%) 6 (1.6%)
Education level
University degree 58 (7.4%) 41 (7.2%) 28 (6.5%) 25 (6.2%) 24 (6.5%)
Apprenticeship 600 (76.3%) 440 (77.2%) 333 (77.1%) 312 (77.8%) 286 (77.1%)
Without apprenticeship 128 (16.3%) 89 (15.6%) 71 (16.4%) 64 (16.0%) 61 (16.4%)
Employment status
Employed 58 (7.4%) 37 (6.5%) 31 (7.2%) 27 (6.7%) 29 (7.8%)
Unemployed 8 (1.0%) 9 (1.6%) 9 (2.1%) 8 (2.0%) 6 (1.6%)
Pensioner 710 (90.3%) 517 (90.7%) 385 (89.1%) 361 (90.0%) 329 (88.7%)
Other 10 (1.3%) 7 (1.2%) 7 (1.6%) 5 (1.2%) 7 (1.9%)
Cognitive impairment 65 (8.3%) 56 (9.8%) 39 (9.0%) 36 (9.0%) 31 (8.4%)
Hypertonia 655 (83.3%) 485 (85.1%) 362 (83.8%) 341 (85.0%) 314 (84.6%)
Diabetes mellitus type ½ 274 (34.9%) 56 (37.9%) 166 (38.4%) 157 (39.2%) 147 (39.6%)
Dementia 54 (6.9%) 44 (7.7%) 34 (7.9%) 31 (7.7%) 26 (7.0%)
Depression 126 (16.0%) 98 (17.2%) 74 (17.1%) 65 (16.2%) 60 (16.2%)
Mental illness 63 (8.0%) 51 (8.9%) 40 (9.3%) 37 (9.2%) 31 (8.4%)
Cancer 84 (10.7%) 63 (11.1%) 46 (10.6%) 44 (11.0%) 43 (11.6%)
+ stroke risk factors (C = “Congestive heart failure” - 1 score point; H = “Hypertension” - 1 score point; A = Age ≥ 75 -2 score points; D = “Diabetes mellitus” - 1 score point; S = “Stroke/TIA” - 2 score points; V = Vascular disease
- 1 score point; A = Age: 65–74 - 1 score point; S = “Sex category: female” - 1 score point).















Table 2 Distribution of responses to ABQ-items*
Item Mean Median SD Skewness
Item 1: “I fully understand what my doctor, nurse or the people at my pharmacy have explained to me so far”.+ 1.58 1.00 0.700 1.082
Item 2: „I can mention the names of my medicines and their scope without hesitation”.+ 2.33 2.00 0.975 0.149
Item 3: „I trust my doctor and agree to my therapy plan together with him”.+ 1.28 1.00 0.512 1.846
Item 4: “My medications help me only if I take them absolutely regularly as recommended”.+ 1.27 1.00 0.512 1.961
Item 5: „Medicines are all poisonous. You should avoid taking medicines at all if possible”. 1.82 2.00 0.902 0.849
Item 6: „I feel basically healthy. Therefore I am sometimes unsure whether I really have to take my medicines daily”. 1.79 2.00 0.869 0.971
Item 7: „I take my medicines every day automatically at a fixed time or on fixed occasions”.+ 1.36 1.00 0.609 1.847
Item 8: „I feel that co-payments for medicines are a great burden”. 2.66 3.00 1.059 −0.135
Item 9: „I frequently forget things on an everyday basis”. 2.32 2.00 0.906 0.435
Item 10: „Generally I often feel bad, and sometimes I feel discouraged and depressed.” 2.24 2.00 0.908 0.329
Item 11: „I frequently have problems taking my medications or it is difficult for me to keep me on the
accompanying conditions of the medication intake”.
1.73 1.50 0.902 1.184
Item 12: „I have to overcome obstacles to my healthcare”. 2.03 2.00 1.120 0.678
Item 13: „I really would need help on an everyday basis (and particularly related to my treatment
with medicines). But I do not get any help”.
1.55 1.00 0.855 1.565
Item 14: „I am really frightened of the side effects of my medicines.” 1.91 2.00 0.854 0.797
Item 15a: „In case I already noticed or in case I would notice side effects related to my medicines: I have
talked or would talk to my doctor about them as soon as possible”.+
1.28 1.00 0.605 2.543
Item 15b: „In case I already noticed or in case I would notice side effects related to my medicines: I have
stopped/would stop my medications or took/would take less of them”.
1.80 1.50 0.976 1.005
*Questionnaire was applied in German; translation into English has been done by the authors; score per item 1–4; n = 432 patients/respondents.
+This item was reverse coded.
Bold numbers represent maximum/minimum values.
ABQ: Adherence Barriers Questionnaire, SD: Standard Deviation.
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(Table 3). Statement 6 of the questionnaire (“I feel basic-
ally healthy. Therefore I am sometimes unsure whether I
really have to take my medicines daily.”) showed the
lowest item-scale correlation (0.225), and Cronbach’s α
increased to 0.817 if this item was deleted. Furthermore,
item 5 (“Medicines are all poisonous. You should avoid
taking medicines at all if possible.”) demonstrated a low
item-total correlation coefficient (0.263). Deleting this
item led to an increased Cronbach’s α of 0.815. Ad-
ditionally, statement 15a with an item-scale correlation
coefficient of 0.274 was below the critical threshold of
0.3, but in this case, removing the item led to a de-
creased internal consistency (α = 0.812). Consequently,
the ABQ questionnaire was reduced by removing items
5 and 6, and the examination of the internal consistence
reliability was revised (Table 3). Item-total correlation in
the reduced 14-item-ABQ scale ranged from 0.265 to
0.640, and upon removing items 5 and 6, the Cronbach’s
α increased to 0.820.
Internal validity
During development of the questionnaire, four subscales
were originally defined (medication-related adherence bar-
riers, health care system-related barriers, and intentionalas well as unintentional barriers). The corresponding
items were initially assigned to these scales on the basis of
their content. Factor analysis of the original ABQ-scale (16
items) based on eigenvalues also suggested a four-factor
solution, which explained 55.72% of the variance. How-
ever, factor analysis based on the reduced ABQ-scale
(without items 5 and 6) identified a three-factor solution
(Table 4). This three-factor solution still explains more
than 50% of the variance (52.88%), which supported the
decision to reduce the original scale (parallel to the advan-
tage in terms of ease of use for respondents). Factor 1
(representing intentional adherence barriers) demon-
strated an eigenvalue of 4.459 and accounted for 31.9% of
the variance. In whole, five items load on this factor
(Table 4). The second component containing five items
can be labelled as subscale describing medication- or
health care system-related adherence barriers; it had an
eigenvalue of 1.864 and explained 13.3% of the variance.
Finally, items 1 and 2 as well as items 9 and 10 can be
summarised as unintentional adherence barriers. These
items showed a maximum loading on the third factor. Fac-
tor 3 had an eigenvalue of 1.080 and explained 7.7% of the
variance.
For the first subscale (intentional adherence barriers),
Cronbach’s α was 0.653 and the item-total correlations
Table 3 Item-total correlations for the original and the reduced ABQ
Item Original 16-item ABQ Reduced 14-item ABQ











Item 1: “I fully understand what my doctor, nurse or the people at my pharmacy have
explained to me so far”.
0.599 0.795 0.634 0.798
Item 2: „I can mention the names of my medicines and their scope without hesitation”. 0.371 0.808 0.397 0.813
Item 3: „I trust my doctor and agree to my therapy plan together with him”. 0.461 0.805 0.443 0.811
Item 4: “My medications help me only if I take them absolutely regularly as recommended”. 0.394 0.808 0.375 0.814
Item 5: „Medicines are all poisonous. You should avoid taking medicines at all if possible”. 0.263 0.815 - -
Item 6: „I feel basically healthy. Therefore I am sometimes unsure whether I really
have to take my medicines daily”.
0.225 0.817 - -
Item 7: „I take my medicines every day automatically at a fixed time or on fixed occasions”. 0.351 0.809 0.326 0.816
Item 8: „I feel that co-payments for medicines are a great burden”. 0.400 0.807 0.395 0.814
Item 9: „I frequently forget things on an everyday basis”. 0.416 0.804 0.431 0.81
Item 10: „Generally I often feel bad, and sometimes I feel discouraged and depressed”. 0.534 0.796 0.567 0.799
Item 11: „I frequently have problems taking my medications or it is difficult for me to
keep me on the accompanying conditions of the medication intake”.
0.634 0.789 0.640 0.793
Item 12: „I have to overcome obstacles to my healthcare”. 0.505 0.798 0.546 0.801
Item 13: „I really would need help on an everyday basis (and particularly related to
my treatment with medicines). But I do not get any help”.
0.600 0.792 0.610 0.796
Item 14: „I am really frightened of the side effects of my medicines”. 0.424 0.804 0.393 0.812
Item 15a: „In case I already noticed or in case I would notice side effects related to my
medicines: I have talked or would talk to my doctor about them as soon as possible”.
0.274 0.812 0.265 0.819
Item 15b: „In case I already noticed or in case I would notice side effects related to my
medicines: I have stopped/would stop my medications or took/would take less of them”.
0.373 0.808 0.337 0.818
ABQ: Adherence Barriers Questionnaire.
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with regards to the item-total correlation coefficients of
the second subscale (medication- or health care system-
related adherence barriers; α = 0.749) could be observed.
The third subscale (unintentional adherence barriers)
demonstrated a Cronbach’s α of 0.709 and a range of
item-total correlations from 0.433 to 0.551.
The observed overall ABQ score based on the reduced
ABQ-scale (14 items; score of 1–4 per item) ranged from
14 to 52 with a mean of 25.35 (SD = 6.46). A range of 5 to
9 was observed with regards to the scores of the five-item
intentional adherence barriers subscale (mean = 7.00, SD =
2.15). With regards to the five-item medication- or health
care system-related adherence barriers subscale and the
four-item unintentional adherence barriers subscale, scores
from 5 to 20 (mean = 9.89, SD = 3.41) and from 4 to 16
(mean = 8.47, SD = 2.57) were observed, respectively.
Figure 1 shows the proportion of patients who were af-
fected by the individual barriers (assuming a barrier existed
in case of an item score of at least 3).
Figure 1 also shows which percentage of patients could
be assigned to the defined groups barriers’ groups/subscales. A patient was assigned to a barriers’ group if
the average score per item belonging to this subscale
was > 2, or at least one subscale item had a score of 4. In
85.9% of the patients, there was at least one adherence
barrier present. More than five barriers were present in
21.1% of the patients. The most commonly mentioned
adherence barrier was the feeling that co-payments were
a great burden. Based on the three subscales, the follow-
ing were present: in 13.2% of the patients, intentional
adherence barriers; in 45.8% of patients, medication/
health care system-related adherence barriers; and in
49.8% of the patients, unintentional adherence barriers.
External validity of the ABQ and tendency towards social
desirability
The overall scores related to the reduced 14-item ABQ
and its subscales correlated significantly with the chosen
validation variables in both external validation analyses
(Table 5). The ABQ score had a stronger correlation
with the modified ARMS score (self-report to identify the
extent of NA) than with the TTR. However, the correla-
tions with the TTR are still significant for all scales of the
Table 4 Factor analysis based on the reduced ABQ*
Factor 1 (subscale of
intentional NA risk)
component loading




Factor 3 (subscale of
unintentional NA risk)
component loading
Eigenvalue 4.459 1.864 1.080
Variance explained 31.850% 13.317% 7.716%
Item
Item 1: “I fully understand what my doctor, nurse or the
people at my pharmacy have explained to me so far”.
0.672
Item 2: „I can mention the names of my medicines and their scope
without hesitation”.
0.678
Item 3: „I trust my doctor and agree to my therapy plan together with him”. 0.795
Item 4: “My medications help me only if I take them absolutely
regularly as recommended”.
0.775
Item 7: „I take my medicines every day automatically at a fixed time or
on fixed occasions”.
0.670
Item 8: „I feel that co-payments for medicines are a great burden”. 0.602
Item 9: „I frequently forget things on an everyday basis”. 0.749
Item 10: „Generally I often feel bad, and sometimes I feel discouraged
and depressed”.
0.763
Item 11: „I frequently have problems taking my medications or it is
difficult for me to keep me on the accompanying conditions of the
medication intake”.
0.755
Item 12: „I have to overcome obstacles to my healthcare”. 0.688
Item 13: „I really would need help on an everyday basis (and particularly
related to my treatment with medicines). But I do not get any help.”
0.796
Item 14: „I am really frightened of the side effects of my medicines”. 0.677
Item 15a: „In case I already noticed or in case I would notice side
effects related to my medicines: I have talked or would talk to my
doctor about them as soon as possible”.
0.659
Item 15b: „In case I already noticed or in case I would notice side
effects related to my medicines: I have stopped/would stop my
medications or took/would take less of them”.
0.385
*Extraction Method: Principal Component Analysis, Rotation Method: Promax.
ABQ: Adherence Barriers Questionnaire, NA: Non-Adherence.
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herence barriers is associated with a decrease in the TTR,
indicating a poorer quality of anticoagulation quality.
Of the 371 patients with available information on
TTR, 35.0% had a poor quality of oral anticoagulation
(TTR < 60%). Patients with a high ABQ score (above the
median of 25), which indicates an increased number of
existing adherence barriers and/or a high strength of these
barriers, were significantly (p < 0.005, Pearson Chi-Square)
more likely to have a poor anticoagulation quality than pa-
tients with a low ABQ score (44.6% versus 27.3%).
Based on the additional five questions with regards to
social desirability, a subgroup of 322 patients with no
strong tendency of responding behaviour towards social
desirability (social desirability score < 5) was identified.
For this subgroup of patients, the ABQ scores (reduced
14-item ABQ), as well as scores related to its subscales,showed a stronger correlation to the modified ARMS
score on a remaining high level of significance (Table 6).
Also, the correlates with the TTR increased, but for the
third subscale of unintentional adherence barriers the
correlation was on an insignificant level. In this sub-
group of patients without a tendency towards socially
desirable responding behaviour, patients with an overall
ABQ score of > 25 were significantly more likely to ex-
perience poor anticoagulation quality (43.8% versus
24.7% affected patients with n = 275 patients, p < 0.005).
Discussion
The psychometric analyses conducted present a high re-
liability and criterion-related validity of the developed
ABQ. The factor structure obtained for the different
subscales supports previous results of the adherence bar-
riers research in showing the importance of three
Figure 1 “Proportion of patients affected by adherence barriers as measured by the ABQ”. The Figure shows the distribution of the
percentage of patients affected by each of the adherence barriers. A patient is defined to be affected by a barrier, if the item score is greater than 2.
Furthermore, the proportion of patients which could be assigned to the defined groups barriers’ groups/subscales is shown. A patient was assigned to
a barriers’ group if the average score per item belonging to this subscale was greater than 2, or at least one subscale item had a score of 4.
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describes intentional adherence barriers. In case these
barriers are present, which we assumed if this subscale
shows an average score of > 2 or one item of this sub-
scale has a score of 4, a patient, because of his attitudes
or negative beliefs, consciously decides to deviate from





Subscale 1 (intentional barriers) 0.4
Subscale 2 (medication-/health care system-related barriers) 0.3
Subscale 3 (unintentional barriers) 0.3
*p < 0.001 (2-tailed).
**p < 0.01 (2-tailed).
***p < 0.05 (2-tailed).
ABQ: Adherence Barriers Questionnaire, ARMS: Adherence to Refills and Medicationunintentional adherence barriers, like forgetfulness,
depression, or lack of knowledge, which belong to the
second ABQ subscale. The third subscale addresses
factors like co-payments, missing help/support or spe-
cial properties of the drugs, and was labelled to be the
subscale describing medication- or health care system-
related barriers.les), the modified AMRS score and the TTR
dified adherence to refills
d medications scale (ARMS)
Time in therapeutic range (TTR)





s scale, TTR: Time in Therapeutic Range.
Table 6 Spearman rank correlation among the ABQ (and subscales), the AMRS score and the TTR for the subgroup of
patients without a high probability of social desirability bias
Modified adherence to refills
and medications scale (ARMS)
Time in therapeutic range (TTR)
N = 298+ N = 275÷
ABQ 0.468* - 0.189**
Subscale 1 (intentional barriers) 0.435* - 0.197**
Subscale 2 (medication-/health care system-related barriers) 0.373* - 0.174**
Subscale 3 (unintentional barriers) 0.332* - 0.101***
+Subgroup of patients with a social desirability score < 5 and with complete ABQ as well as modified ARMS data.
÷Subgroup of patients with a social desirability score < 5 and with complete ABQ, who received vitamin K antagonist and had at least 2 INR values available.
*p < 0.001 (2-tailed).
**p < 0.005 (2-tailed).
***p = 0.094 (2-tailed).
ABQ: Adherence Barriers Questionnaire, ARMS: Adherence to Refills and Medications scale, TTR: Time in Therapeutic Range, INR: International Normalized Ratio.
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as high validity through demonstrating significant corre-
lations with the used adherence self-report instrument
(modified ARMS) and the clinical outcome TTR. So, the
ABQ can be used as a tool to identify any adherence
barriers that may be present in a patient; in this case, it
is used on an item-specific basis. Furthermore, the pres-
ence of certain adherence barriers groups as defined by
our three subscales can be identified. Thus, the ABQ en-
ables scientists as well as clinical practitioners to align
certain adherence interventions to specific adherence
barriers that may be present in specific patients.
Limitations
We acknowledge some limitations of our analysis. First,
because of data limitations, we were only able to use AF
patients treated by GPs for our validation. This may
limit generalizability to other settings. Particularly, pa-
tients with AF tend to be older and more morbid.
Therefore, further research is needed to show the effec-
tiveness of the questionnaire in other settings. Neverthe-
less, the analysed patient samples were characterised by
a high average rate of medication dependency and oc-
currence of chronic diseases. Second, we used the ABQ
in a German treatment setting only and there probably
exist country specific adherence barriers (e. g. out-of-
pocket cost). It needs to be seen whether the ABQ
shows similar validity and consistency when applied in
other countries. Third, our survey design did not facili-
tate the assessment of test-retest reliability that should
be proven in further investigations. Fourth, 138 out of
570 patients (24.2%) did not complete the ABQ. The
characteristics of these patients do not differ from those
of all ACT-AF patients or from those of the patients
who completed the ABQ without any gap (Table 1).
However, most of these patients (n = 76) did not
complete the other parts of the survey as well so that
non-response to the ABQ items seems not to be anABQ-specific phenomenon. Of those patients who did
complete the other questions of the survey but could
not complete the ABQ, only one patient did not answer
any of ABQ items, and a large proportion of patients
only missed one (67.7%) or two (12.9%) items of the
ABQ. Item 15b was the item with the highest number of
gaps (35 of 62 patients 56.4%). It is possible that patients
consider items 15a and 15b as alternative items and
think they finished the questionnaire after answering
item 15a. A renumbering of these items should be done
and the effect should be proven in further investigations.
Fifth, we decided to use self-reported NA and TTR as
external validation criteria. So, there might be more ob-
jective measures, which are more suitable to validate our
tool (e. g. data derived from medication event monitor-
ing systems or laboratory data). However, self-reported
NA and TTR were chosen because they seemed to be
both objective measures of medication adherence/clin-
ical effectiveness of medication without being influenced
by patient behaviour within the setting. The ARMS was
involved in a regular survey within the prospective study
period and the INR values for calculating the TTR were
measured in a regular care setting. Nevertheless, the
ABQ correlated stronger with the ARMS than with the
TTR, which may be due to several reasons. On the one
hand, the TTR is influenced by other factors, like nutri-
tion. On the other hand, it might be that both the ABQ
and the ARMS scores are affected by a self-report bias.
The data were collected at a scheduled GP appointment.
To the extent that appointment keeping indicates com-
pliance with health behaviour, patients who completed
the questionnaire may have been more likely to be ad-
herent to medication therapy as well. At the same time
the social desirability bias may be higher when patients
answer in a medical environment. However, additional
questions were included to control for the tendency of
patients to response in a socially desirable manner, and
separate subgroup analyses were conducted. Our
Müller et al. BMC Health Services Research  (2015) 15:153 Page 11 of 12analysis shows that the predictive power of the ABQ im-
proves if socially desirable responding behaviour is ex-
cluded. Based on this analysis, future research may
explore whether a more sophisticated ABQ item scoring
methodology adjusting ABQ scores by “socially desirabil-
ity scores” improves the efficacy of the ABQ in identify-
ing existing adherence barriers.
Conclusions
The ABQ is a practical, reliable, and valid instrument for
identifying specific barriers to medication-related adher-
ence. The questionnaire has the potential to support the
physician-patient communication as well as the imple-
mentation of tailored interventions to improve adherence.
Future research is required to examine the usefulness of
the ABQ in other settings and its ability to identify patient
perception/behaviour changes over time, which may be
important for the measurement of success of adherence
interventions.Additional files
Additional file 1: Overview – Review of literature regarding factors
associated with medication related NA (2008–2010); the table
shows the results of the conducted review of the literature in
2008–2010 with regards to reasons of non-adherence.
Additional file 2: Overview – Review of literature regarding factors
associated with medication related NA (2011–2013); the table
shows the results of the conducted review of the literature in
2011–2013 with regards to reasons of non-adherence.
Additional file 3: Modified “Adherence to Refills and Medications
Scale – ARMS”; in the document the used questionnaire to measure
self-reported non-adherence can be found.
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